当前位置: 首页 > 期刊 > 《中国实用医药》 > 2009年第2期
编号:11727493
多药耐药蛋白P-糖蛋白的研究进展(3)
http://www.100md.com 2009年1月15日 《中国实用医药》 2009年第2期
     [10] Ramachandran C,Wellham LL.Effect of MDRI phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.Anticancer Res,2003,23(3B):2681-2690.

    [11] Wang H,Chen XP,Qiu FZ.Overcoming multi-drug resistance byanti-mdrlribozyme.World J Gastroenterol,2003,9(7):1444-1449.

    [12] ChenL,LiuY.Reversion of multidrug resistance in vitro of lung adenocarcinoma by MDR1 ribozyme.Zhonghua Zhong Liu Za Zhi,2000,22(3):189-191.

    [13] Kiehntopf M,Herrmann F,Brach MA.Functional NF-IL6/CCAAT enhancer-binding protein is required for tumor necrosis factor α-inducible expression of the granulocyte colony-stimulating factor (CSF),but not the granulocyte/macrophage CSF or interleukin 6 gene in human fibroblasts.J Exp Med,1995,181(2):793-798.

    [14] Mayer LD,Lim KT,Hartley D.Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.J Exp Ther Oncol,2002,2(2):107-120.

    [15] 白符,隋丽华,娄阁.用外周血、腹水代替卵巢癌组织检测MDR1可行性研究.中国肿瘤临床,2001,28(l):18-20., 百拇医药(李 睿 徐海帆)
上一页1 2 3